AbCellera Biologics (ABCL) EPS (Weighted Average and Diluted): 2020-2023
Historic EPS (Weighted Average and Diluted) for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$0.17.
- AbCellera Biologics' EPS (Weighted Average and Diluted) fell 70.00% to -$0.17 in Q4 2023 from the same period last year, while for Dec 2023 it was -$0.52, marking a year-over-year decrease of 204.00%. This contributed to the annual value of -$0.55 for FY2024, which is 7.84% down from last year.
- Latest data reveals that AbCellera Biologics reported EPS (Weighted Average and Diluted) of -$0.17 as of Q4 2023, which was down 70.00% from -$0.10 recorded in Q3 2023.
- AbCellera Biologics' 5-year EPS (Weighted Average and Diluted) high stood at $0.54 for Q1 2022, and its period low was -$0.17 during Q4 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is $0.04, with a median of -$0.05 in 2021.
- As far as peak fluctuations go, AbCellera Biologics' EPS (Weighted Average and Diluted) spiked by 3,800.00% in 2021, and later plummeted by 450.00% in 2023.
- Over the past 4 years, AbCellera Biologics' EPS (Weighted Average and Diluted) (Quarterly) stood at $0.44 in 2020, then crashed by 56.82% to $0.19 in 2021, then slumped by 152.63% to -$0.10 in 2022, then tumbled by 70.00% to -$0.17 in 2023.
- Its last three reported values are -$0.17 in Q4 2023, -$0.10 for Q3 2023, and -$0.11 during Q2 2023.